{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:12:37Z","timestamp":1790251957007,"version":"4.1.0"},"reference-count":25,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101095052"],"award-info":[{"award-number":["101095052"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Associations between serum adalimumab trough levels and disease activity were examined using longitudinal data from a 48-week randomised phase III trial including patients with tumour necrosis factor inhibitor-na\u00efve rheumatoid arthritis with active disease starting adalimumab treatment. Disease activity was classified according to 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate and C reactive protein (CRP) levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Adalimumab trough levels were recorded longitudinally for 336, 330 and 302 patients at weeks 12, 24 and 48, respectively. All patients received concomitant methotrexate. Median adalimumab trough levels were 6.4\u2009mg\/L (IQR 3.4\u20139.5) at week 12, 7.5\u2009mg\/L (IQR 3.5\u201310.9) at week 24 and 7.6\u2009mg\/L (IQR 3.6\u201312.0) at week 48. In serial serum samples from weeks 12, 24 and 48, trough levels \u22653.9\u2009mg\/L were associated with DAS28 remission (OR 3.88 (95% CI 1.80, 8.38), p&lt;0.001) and lower CRP levels (p&lt;0.001). Week 12 trough levels \u22653.5\u2009mg\/L were associated with DAS28 low disease activity at week 24 (OR 2.62 (1.50, 4.56), p&lt;0.001) and remission at week 48 (OR 1.99 (1.02, 3.88), p=0.04), as well as lower CRP levels at both time points (p&lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adalimumab trough levels above 4.0 mg\/L were associated with remission\/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004888","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:30:16Z","timestamp":1731537016000},"page":"e004888","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02744755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-0223","authenticated-orcid":false,"given":"Johanna Elin","family":"Gehin","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf Anton","family":"Klaasen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Klami Kristianslund","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Jyssum","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David John","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen Andre","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-3696","authenticated-orcid":false,"given":"Silje Watterdal","family":"Syversen","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L\u00f8vik","family":"Goll","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"2025090312354485000_10.4.e004888.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090312354485000_10.4.e004888.2","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312354485000_10.4.e004888.3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/14712598.2023.2273938","article-title":"Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway","volume":"23","author":"Goll","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025090312354485000_10.4.e004888.4","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/764518","article-title":"Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers","volume":"2013","author":"Arora","year":"2013","journal-title":"Int J Rheumatol"},{"key":"2025090312354485000_10.4.e004888.5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.semarthrit.2020.06.020","article-title":"Discontinuation of biologic therapy due to lack\/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort","volume":"50","author":"Movahedi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312354485000_10.4.e004888.6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.semarthrit.2020.02.011","article-title":"The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients","volume":"50","author":"van Mulligen","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312354485000_10.4.e004888.7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kead525","article-title":"Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases","volume":"63","author":"Jyssum","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312354485000_10.4.e004888.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211781"},{"key":"2025090312354485000_10.4.e004888.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00559-1"},{"key":"2025090312354485000_10.4.e004888.10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.42764","article-title":"Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases","volume":"76","author":"Syversen","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025090312354485000_10.4.e004888.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21316"},{"key":"2025090312354485000_10.4.e004888.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222155"},{"key":"2025090312354485000_10.4.e004888.13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002216","article-title":"Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider","volume":"8","author":"Krieckaert","year":"2022","journal-title":"RMD Open"},{"key":"2025090312354485000_10.4.e004888.14","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/rheumatology\/keac564","article-title":"Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis","volume":"62","author":"Hum","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312354485000_10.4.e004888.15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clinthera.2018.01.002","article-title":"Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial","volume":"40","author":"Goss","year":"2018","journal-title":"Clin Ther"},{"key":"2025090312354485000_10.4.e004888.16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","article-title":"Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up","volume":"55","author":"Chen","year":"2016","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312354485000_10.4.e004888.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"2025090312354485000_10.4.e004888.18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","article-title":"Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study","volume":"34","author":"Wiland","year":"2020","journal-title":"BioDrugs"},{"key":"2025090312354485000_10.4.e004888.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090312354485000_10.4.e004888.20","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"2025090312354485000_10.4.e004888.21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatol (Sunnyvale)"},{"key":"2025090312354485000_10.4.e004888.22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4155\/bio-2023-0152","article-title":"Signal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar","volume":"16","author":"Guerrieri","year":"2024","journal-title":"Bioanalysis"},{"key":"2025090312354485000_10.4.e004888.23","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"key":"2025090312354485000_10.4.e004888.24","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"key":"2025090312354485000_10.4.e004888.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201544"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:35:58Z","timestamp":1756928158000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,13]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/rmdopen-2024-004888"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004888","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}